Effectiveness of BBV152/Covaxin and AZD1222/Covishield vaccines against severe COVID-19 and B.1.617.2/Delta variant in India, 2021: a multi-centric hospital-based case-control study-Reference-Cited by-同舟云学术

Effectiveness of BBV152/Covaxin and AZD1222/Covishield vaccines against severe COVID-19 and B.1.617.2/Delta variant in India, 2021: a multi-centric hospital-based case-control study

Published:2022-09 Issue: Volume:122 Page:693-702
ISSN:1201-9712
Container-title:International Journal of Infectious Diseases
language:en
Short-container-title:International Journal of Infectious Diseases

Author:

Bhatnagar Tarun,Chaudhuri Sirshendu^ORCID,Ponnaiah Manickam,Yadav Pragya D,Sabarinathan R,Sahay Rima R^ORCID,Ahmed Faheem,Aswathy S,Bhardwaj Pankaj^ORCID,Bilimale Anil,Kumar M Santhosh,Logaraj M.,Narlawar Uday,Palanivel C,Patel Prakash,Rai Sanjay K,Saxena Vartika,Singh Arvind,Thangaraj Jeromie WV,Agarwal Ashwini,Alvi Yasir^ORCID,Amoghashree ,Ashok P,Babu Dinesh^ORCID,Bahurupi Yogesh^ORCID,Bhalavi Sangita,Behera Priyamadhaba^ORCID,Biswas Priyanka Pandit^ORCID,Charan Jaykaran^ORCID,Chauhan Nishant Kumar^ORCID,Chetak KB,Dar Lalit,Das Ayan,Deepashree R,Dhar Minakshi,Dhodapkar Rahul^ORCID,Dipu TS,Dudeja Mridu,Dudhmal Manisha,Gadepalli Ravisekhar,Garg Mahendra Kumar^ORCID,Gayathri AV,Goel Akhil Dhanesh^ORCID,Gowdappa H Basavana,Guleria Randeep,Gupta Manoj Kumar,Islam Farzana,Jain Mannu,Jain Vineet,Jawahar M Lanord Stanley,Joshi Rajendra,Kant Shashi^ORCID,Kar Sitanshu Sekhar^ORCID,Kalita Deepjyoti^ORCID,Khapre Meenakshi^ORCID,Khichar Satyendra,Kombade Sarika Prabhakar,Kohli Sunil^ORCID,Kumar Abhinendra,Kumar Anil,Kumar Deepak,Kulirankal Kiran G,Leela KV,Majumdar Triparna,Mishra Baijayantimala,Misra Puneet,Misra Sanjeev,Mohapatra Prasanta Raghab^ORCID,Murthy M Narayana,Nyayanit Dimpal A,Patel Manish,Pathania Monika,Patil Savita,Patro Binod Kumar,Jalandra Ramniwas,Rathod Pragati,Shah Naimesh,Shete Anita,Shukla Deepak,Shwethashree M,Sinha Smita,Sumana MN,Surana Ashish,Trikha Anjan,Tejashree A,Venkateshan Mahalingam^ORCID,Vijaykrishnan G,Wadhava Sarita,Wig Naveet,Gupta Nivedita,Abraham Priya,Murhekar Manoj V

Funder

Indian Council of Medical Research

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference32 articles.

1. Regression analysis with multicollinearity;Afifi,2004

2. The conundrum of two-dose interval of ChAdOx1 nCOV-19 corona virus vaccine: way ahead;Bobdey;Med J Armed Forces India,2021

3. Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a, double-blind, randomised, controlled phase 3 trial;Ella;Lancet,2021

4. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial;Ella;Lancet Infect Dis,2021

5. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial;Ella;Lancet Infect Dis,2021

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. COVID-19 Vaccines and Adverse Effects of SARS-CoV-2 in Recovered Patients of COVID-19: An In-depth Review;Journal of Pure and Applied Microbiology;2024-08-29

2. Longitudinal Follow-Up Study on the Side Effects of COVID-19 Vaccines: A Telephonic Questionnaire Approach;Cureus;2024-06-22

3. Serosurveillance of COVID-19 amongst health care workers in a teaching institution – A prospective cohort study in Puducherry district;Journal of Family Medicine and Primary Care;2024-05

4. Utility of COVID-19 Seropositive Plasma as Convalescent Plasma: An Immune and Neutralization Antibody Seroprevalence Analysis in Blood Donors for Future Potential Pandemic Readiness;Cureus;2024-03-28

5. IgG responses against SARS-CoV-2 vaccines AZD1222 and BBV-152 and breakthrough infections among health care workers in southern India;Heliyon;2024-02